NASDAQ$DERM
Journey Medical Corp · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Journey Medical reported full-year financial results for 2023, showing revenue growth and cost savings.
Journey Medical Corporation reported full-year revenue of $79.2 million, a 7% increase from 2022. The company achieved $15.6 million in operating cost savings, exceeding initial guidance. A New Drug Application for DFD-29 was accepted by the FDA, with a PDUFA goal date of November 4, 2024.
- Full-year revenue reached a record high, driven by Qbrexza® licensing agreement and core dermatology product sales.
- Operating cost savings of $15.6 million were achieved, surpassing initial guidance.
- New Drug Application for rosacea treatment candidate DFD-29 was accepted for FDA review.
- Company is positioned for growth with a portfolio of dermatology brands, sales force, and the potential launch of DFD-29 in early 2025.
Headline financials
Revenue & EPS history
Journey Medical · Revenue · Quarterly
$15.3M
Forward guidance
Journey Medical anticipates continued growth and value creation based on its dermatology portfolio, sales force, streamlined cost structure, and the potential launch of DFD-29.
Tailwinds
- Portfolio of recognized dermatology brands
- Proven sales force
- Streamlined cost infrastructure
- Potential to launch DFD-29 in early 2025
- DFD-29 has the potential to become the only oral, systemic therapy
Headwinds
- Products and product candidates are subject to time and cost intensive regulation and clinical testing
- A substantial portion of sales derive from products that may become subject to third-party generic competition
- Revenue is dependent mainly upon sales of dermatology products
- Competition could limit products’ commercial opportunity and profitability
- The dependence of the success of business on the successful development and regulatory approval of the DFD-29 product candidate
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
-2.9%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+5.1%
Avg return
30 days after
39%
9 / 23 earnings
Positive
+22.0%
Q1 2025
Best reaction
-26.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -26.8% | -1.1% | — | |
| Q1 2026 | +3.0% | +24.4% | +26.5% | |
| Q3 2025 | -15.3% | -12.4% | -15.5% | |
| Q2 2025 | -15.1% | -18.0% | -16.7% | |
| Q1 2025 | +22.0% | +15.2% | +13.6% | |
| Q4 2024 | -3.6% | -2.8% | +21.7% | |
| Q3 2024 | -8.2% | -7.5% | -9.3% | |
| Q2 2024 | -3.2% | -11.0% | -3.8% | |
| Q1 2024 | +2.8% | -1.7% | +69.2% | |
| Q4 2023 | -14.1% | -3.9% | -9.4% | |
| Q3 2023 | +15.7% | +14.8% | +105.5% | |
| Q2 2023 | +14.0% | +4.7% | +21.5% | |
| Q1 2023 | -10.1% | -23.2% | +44.9% | |
| Q4 2022 | +3.1% | +13.1% | +26.3% | |
| Q3 2022 | -8.7% | -9.2% | -27.2% | |
| Q2 2021 | -4.3% | -7.0% | -30.1% | |
| Q2 2022 | -4.3% | -7.0% | -30.1% | |
| Q1 2022 | -12.3% | +5.1% | +0.8% | |
| Q1 2021 | -12.3% | +5.1% | +0.8% | |
| Q4 2021 | +5.4% | +6.1% | -1.8% | |
| Q3 2020 | +3.4% | -0.1% | -24.3% | |
| Q4 2020 | +3.4% | -0.1% | -24.3% | |
| Q3 2021 | +0.0% | +0.0% | -25.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro